US › Healthcare

Veru Inc (VERU)

US · Healthcare · Biotechnology

$2.39+3.02%

Last close · 2026-09-17

Latest quarter · ended 2026-06-30

Revenue

Net profit

$-7.0M

EPS

$-0.30

EPS estimate

$-0.32

EPS came in at -0.30 against a street estimate of -0.32 — a beat of 6.3%.

Key statistics

Market cap

$41.6M

Forward P/E

117.6

P/B

1.47

Book value

$1.66

EPS (TTM)

$-0.61

52-week high

$4.59

52-week low

$2.05

50-day MA

$2.54

200-day MA

$2.49

Beta

-1.16

Analyst view

Analysts rate Veru Inc a buy (4 buy, 1 hold, 0 sell out of 5) with an average price target of $24.50.

Shareholding

Insiders

9.22%

Institutions

19.64%

Largest institutional holders

Fund	Stake
Alyeska Investment Group, L.P.	5.87%
Vanguard Capital Management, LLC	3.16%
Oppenheimer & Co Inc	1.15%
Geode Capital Management, LLC	1.08%
GSA Capital Partners LLP	0.92%
Summit Financial LLC	0.83%
Ikarian Capital, LLC	0.78%
BlackRock Inc	0.67%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Veru Inc — free to start.

Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc Merck & Company Inc UnitedHealth Group Incorporated Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Amgen Inc Novo Nordisk A/S Gilead Sciences Inc Abbott Laboratories

Data updated 2026-09-18.